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Objectives: Within the National Institute for Health and Care Excellence (NICE) 
Appraisal process, quality adjusted life years (QALYs) are regarded as having equal 
weighting. However, in January 2009, NICE introduced the end-of-life (EOL) crite-
ria, giving more weight to QALYs for life-extending, and EOL interventions. In May 
2014, the Scottish Medicines Consortium (SMC) introduced the Patient and Clinician 
Engagement (PACE) process for evaluating EOL medicines and medicines used to 
treat very rare conditions, to allow a more flexible approach to considering such 
medicines. These two initiatives allow a greater cost per QALY gained willingness-
to-pay threshold than usual in the United Kingdom (UK), however there are differ-
ences in their requirements and outcomes. The aim of this study was to compare 
the process and conclusions drawn by NICE and the SMC for health technology 
appraisal submissions either meeting NICE EOL criteria after May 2014, or being 
accepted into the PACE process based on EOL. MethOds: All technologies reviewed 
under the PACE process, NICE EOL criteria or both were identified. Information 
collected included whether EOL criteria were met, incremental cost effectiveness 
ratio (ICER) and SMC and NICE decisions. Results: In total, 15 technologies were 
reviewed. Of the 15, 14 were reviewed under PACE; 8 were given positive SMC Advice, 
3 were given restricted positive SMC Advice and 3 were given negative SMC Advice. 
Of the 14 technologies reviewed under the PACE process, 7 were reviewed by NICE, 
4 met EOL criteria, 2 of which were given positive NICE Guidance. cOnclusiOns: 
Of those technologies considered by both NICE and SMC since May 2014, fewer met 
the NICE EOL criteria than the PACE EOL criteria, and fewer still received positive 
NICE Guidance. There are differences in access to interventions for diseases with 
short life expectancies within the UK, although further research into the changing 
Cancer Drugs Fund is needed.
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Objectives: To analyse the causes and financial implications of the variabil-
ity of use of A&E resources (visits, admissions) across Spanish Hospitals and 
Regions MethOds: Review of the Configuration Management DataBase Set (CMDB) 
and Hospital Discharge Statistics during the period 2010-2012, using a multivari-
ate analyses controlling for factors like: region, sex, age, income, etc. to explain 
the relative rate to average and variations within and between regions. Results: 
There is a significant variation between and within regions and hospitals, which 
is mostly explained by personal income, distance to hospitals, availability of alter-
natives in Primary Care, and, quite interestingly (p< 0.05 within Hospitals of same 
regions), size of hospital measured in terms of available beds. This impacts on the 
resource allocation, new hospitals to be erected -new investments- and cost per 
patient. cOnclusiOns: Variability of A&E resource utilisation (frequency of visits, 
hospitalizations) is greatly explained using a multidimensional approach within and 
betwen regions, having more than 80% explanative variables laying into Personal 
Income, Distance to Hospital, Available Beds, and Primary Care Ambulatory alterna-
tives. Other variables were not deemed to be significant.
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Objectives: Differential pricing (DPR) is based on the economic concept of price 
discrimination. DPR is reported as a potential effective way to: (1) Improve access to 
medicines in lower income countries whilst maintaining welfare in higher income 
countries; (2) Preserve incentives for R&D through higher prices in high income 
countries. This study aimed to assess the current situation of DPR for pharmaceu-
ticals in the European Union (EU). MethOds: A literature review was conducted 
in MEDLINE®, WHO, OECD, and EU Commission websites, complemented by a grey 
literature search. Key DPR principles were identified and current implementation 
challenges in the EU were assessed. Results: Ramsey (1927) developed a well-
known DPR theory stating that prices should differ across markets according to 
inverse relation to demand elasticity, with more price-sensitive users, (i.e. lower 
income countries) charged at a lower price than less-price sensitive users. Another 
approach to DPR proposed by Danzon et al. (2013), called “value-based differential 
pricing”, would be to have prices reflecting utilization in each country. DPR is highly 
discussed among national/EU institutions and industry given the differences in 
GDP per capita and price levels of EU countries. However, several challenges were 
reported to limit DPR implementation: (1) DPR scheme is based on average per capita 
income; (2) Manufacturers attempt to apply higher price in low income markets 
and lower price in high income markets; (3) Differential distribution margins; (5) 
Risk of parallel trade; (6) Use of external reference pricing (ERP) where prices and 
undisclosed rebates in high income countries drive high prices in lower income 
countries. cOnclusiOns: DPR is widely debated to enhance access to innova-
tive expensive medicines in the low income market. However, DPR optimization 
requires wide coordination and interaction, between the countries and the industry 
to minimize various counteracting policies and initiatives.
PHP72
InVestIgatIng tHe aCCessIbIlIty of unInsured PoPulatIon to HealtH 
serVICes In greeCe
Polyzou P1, Kaitelidou D1, Galanis P1, Siskou O2, Kalogeropoulou M2, Konstantakopoulou 
O2
1National and Kapodistrian University of Athens, Athens, Greece, 2Center for Health Services 
Management and Evaluation, National and Kapodistrian University of Athens, Athens, Greece
Objectives: One of the most significant effects of economic crisis in Greece is the 
rising number of unemployed and uninsured citizens. A large percentage of the 
attempt to identify barriers to access. This study aims to investigate the factors 
that act as determinants of HSU for the Greek population, as well as highlight 
their evolution since 2006. MethOds: The study was based on data collected by 
three cross-sectional health interview surveys conducted by the National School of 
Public Health, Athens, Greece, in 2006, 2011 and 2015 with representative national 
samples of 4003, 6569 and 2012 adults respectively. Respondents were asked to 
answer a series of questions on HSU and report their demographic characteris-
tics. Results: A significant decrease in the basic measures of HSU between 2006 
and 2015 was detected. In 2006, 74.6% of respondents answered that they had used 
a health service in the last 12 months, whereas in 2015 the corresponding figure 
was only 46.5%. There was a statistically significant association between HSU and 
gender of respondents, with females utilizing the services at a considerably higher 
rate (52.9%) than men (38.6%). The degree of non utilization health services was 
not changed substantially in these surveys, however the reasons for not using the 
services were found to change and brought up statistically significant associa-
tions with age, income and occupation of respondents. It is noteworthy that the 
percentage of population unable to access healthcare due to inability to pay was 
5.9%, 8.5% and 27.4% in 2006, 2011 and 2015 respectively. cOnclusiOns: It is 
evident that demographic and socioeconomic determinants influence the HSU. 
The findings highlight the problem of social inequalities as a major issue of health 
policy.
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Objectives: Access to medicines is usually given under the regulatory approvals and 
subsequent coverage decisions, after efficacy and safety have been proven by clinical 
trials. Recently, systems to enable exceptional early access have been explored to meet 
significant, unmet, and urgent medical needs for frontier medicines. In Japan, the 
Advanced Medical Care B system (AMCB) is already in operation. Two other systems, 
the Compassionate Use system (CU) and the Patient-Initiated Mixed-Care system 
(PIMC), are planned to start. The objective of this study is to understand the design and 
institutional positioning of these three systems, identifying opportunities for further 
improvements. MethOds: A documentary research was conducted by analyzing 
government documents and the Diet Record. Results: For the AMCB system, the 
review board designates technologies that include the use of unapproved medicines 
or off-label indications, after requests from health care professionals. The CU sys-
tem is to be fully introduced in 2015 and targets medicines at later stages of clinical 
development, opening up opportunities for patients who are not eligible for the tri-
als. The PIMC system is to start in 2016 and focused on medicines or patients that 
are not covered by the other two systems. The three systems have no legal financial 
aid programs to cover the costs of experimental medicines, while the systems allow 
coverage of other treatment costs than those medicines. Details of the CU and PIMC 
systems are currently under discussion. cOnclusiOns: The scopes of the three 
systems were found to be complementary to one another, covering both unapproved 
medicines and patients excluded from clinical studies. Legal financial aid would be 
worth considering for more equitable and extensive early access.
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Wu J, Liu J, Zhu B, Mao Y
Xi’an Jiaotong University, Xi’an, China
Objectives: China’s New Medical Reform (NMR), which started in 2009, aims at 
improving the equity of basic health service, especially in the less well-off areas. 
The purpose of this study is to know whether the popularity of NMR has allevi-
ate the existing health inequity in rural West China by comparing indicators of 
health equity of rural residents covered by New Rural Cooperative Medical System 
(NRCMS) before and after China’s NMR. MethOds: Related data have been col-
lected respectively from 2860 and 2432 rural residents through random-sampling 
household questionnaire survey in Z County, Shaanxi, China, in November 2009 
(before NMR) and October 2012 (after NMR). The sample residents are divided 
into 5 groups by per capita annual income in families, and equity of health need, 
utilization and benefit have been calculated through Concentration Index (CI) and 
ANOVA. Results: On equity of health need, CIs for two-week morbidity and half-
year prevalence rate of chronic diseases among rural residents of different income 
levels in 2009 and 2012 are -0.0524, -0.0536 and -0.0792, -0.0840 respectively. On 
equity of health service utilization, CIs for treatment of two-week morbidity in 
2009 and 2012 are -0.0096 and -0.0992 respectively; CIs for hospitalization and non-
hospitalization of residents are 0.0032, -0.1712 and -0.0396, -0.1548 respectively. 
On benefit equity, CIs for hospitalization rate of residents in 2009 and 2012 are 
-0.0208 and -0.0712 respectively; CIs for average compensation of hospitaliza-
tion are -0.0212 and -0.1620 respectively. Difference in economic burden caused 
by diseases among residents of different income levels is non-significant after 
the implementation of NMR (P> 0.05). cOnclusiOns: NMR has improved the 
equity of health service need of rural residents to some extent while reduced 
the utilization equity little. Benefit equity is enhanced since low-income resi-
dents benefit more than high-income counterparts from in-patient health service. 
Rural residents’ economic burden caused by diseases has reduced significantly 
after NMR.
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burse different essential medicine causing inequity to access essential medicines. 
Federal ministry of health tried to unify essential list in 10 different cantons by 
Order from 2011 but this has never been fully implemented by all 10 cantonal HIFs. 
In Republic of Srpska (RS) there is one HIF, and 3rd administrative part Brcko District 
(BD) has its own HIF. MethOds: We compered average reimbursed prices from 
main HIFs in B&H for most commonly proscribed primary care medicines based 
on 2014 Annual report on medicines utilization issued by Agency for medicines of 
B&H. Average prices have been taken into account since different presentation of 
the same INN (dosage and number of units in pack) are reimbursed. All prices are 
expressed in EUR and represents prices paid by HIF. Results: Comparing Federal 
MoH proposed reimbursed prices and prices from RS HIF s it is noted that prices are 
higher in RS (+20% on average) except in case of bisoprolol. The highest difference is 
for atorvastatin (+39%). Prices in BD are on average lover for -14% vs Federal prices 
and -43% vs RSHIF prices. There are high differences among cantonal RB prices 
comparing to Federal proposal and among main 3 cantons. Atorvastatin is not reim-
bursed in Tuzla and Zenica Canton, while rosuvastatin is not reimbursed in Tuzla 
Canton and BD. Also different copayment levels are introduced at cantonal HIF level 
causing additional inequalities. cOnclusiOns: Different prices cause inequity to 
access essential medicines for inhabitants living in different administrative regions. 
It also impact market indifferences. Implementation of unified and centralized 
pricing system would positively impact on access to medicines and HIFs spending.
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Objectives: Generally, socioeconomic conditions can be recognised as core determi-
nants of health status. The aim of this study is to identify how the sociodemographic 
characteristics of the population influence self-rated health (SRH) as well as to exam-
ine the relationship between SRH and subjective social status (SSS). MethOds: A 
cross-sectional survey was conducted on a representative national sample of 2012 
adult individuals. Respondents were asked to self-evaluate their social status on a 
10-step ladder-based survey tool where 10 represented the highest subjective social 
stratum. Data were analyzed through an ordinal logistic regression model to identify 
the unique characteristics that exist between SRH, sociodemographic characteristics 
and SSS. Results: Older individuals and chronic patients had a lower probability of 
rating their health high. Odds ratio for older age was 0.74 and for the non existence 
of a chronic disease was 4.30. A relation between social interactions and health levels 
was documented. This can be interpreted by the positive relation (OR= 1.27) between 
SRH and social support, where individuals who reported having more people to rely 
on had a higher probability to self-rate their health higher. In terms of the SSS, there 
is a significant statistical positive association (OR= 1.24) with SRH. It is worth adding 
that the highest percentage of respondents (27.4%) rated their SSS as moderate (step 
5), while 69.5% of the respondents reported a positive health level. cOnclusiOns: 
This study provides evidence on the association between socioeconomic factors and 
SRH among the Greek adult population. This contributes to the understanding of the 
complex inter-relationships leading to health inequalities in societies with prevalent 
socioeconomic disparities. Since Greece is going through a deep economic recession, 
such rising inequalities are observed.
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Objectives: Evidence based medicine has been used for about two decades as meth-
odology for obtaining, evaluating and presenting information on health related topics. 
The present study investigated the question of the appearance of the ideas of evi-
dence based medicine in documents describing the functioning of health care sys-
tems in countries not belonging to the European Union. MethOds: The documents 
available in the European Observatory on Health Systems and Policies database were 
considered to reliable represent the health system of non-European Union countries 
too. Electronic search was carried out, each ‘evidence’ expression was categorised 
afterwards into different topics. Deadline of the search was March, 2015. Results: 
The cumulative length of the documents was 4680 pages; there was no document 
without mentioning the idea of evidence based medicine. Among the altogether 431 
mentionings of evidence based medicine, we were able to categorise 295 representa-
tions of the idea into one of the following 4 topics: 1. resources of health care, 2. health 
technology assessment, 3. organisation of health care and 4. environment of health 
care within the society. Evidence based medicine was mentioned 49 times in connec-
tion with the resources of health care, whereas 20 mentionings were related to health 
technology assessment. Organisation of health care was mentioned together with evi-
dence based medicine at 152 occasions, whereas the idea of evidence based medicine 
was related to the social environment of health care in 74 instances. cOnclusiOns: 
The results of the present data collection indicate that the methodology of evidence 
based medicine has already been widely used within the documents describing health 
systems and policies also in countries not belonging to the European Union.
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Objectives: There was a significant regulation of the inpatient care hospital 
capacity in the last decade in Hungary. The ratio of short- and long term care hos-
population has lost its job and in many cases the insurance capacity.The objective 
of this study was to identify the problems related with the access to health care 
services of Greek and immigrants who visitednon-governmental clinics in Athens, 
in order to receive free of charge health services. The inclusion criteria for participa-
tion in the study was the satisfactory level of understanding the Greek language, 
the lack of insurance or employment or alternatively being under the risk of pov-
erty. MethOds: A cross-sectional study was conducted. The study population con-
sisted of 100 people, Greek and migrants, living in Athens. The participants were> 18 
years. The research team developed a questionnaire that included information about 
sociodemographic characteristics, health status, public healthservices knowledge 
and utilization and difficulties in health services access. The questionnaire was 
completed through interviews. Data analysis was performed with the IBM SPSS 
19.0 (Statistical Package for Social Sciences). Results: The lack of knowledge about 
programs which may provide access to health care services was among the most 
significant findings. More than 90% of the respondents reported that they were not 
informed about the legal arrangements voted recently for the universal coverage of 
uninsured population. Other significant barriers in accessing health care services 
included cost as 92, 1% of the respondents stated that they couldn’t afford to buy 
the recommended treatment and the bureaucratic procedures. cOnclusiOns: 
The last law amendments ensuring accessibility of vulnerable groups to health 
services are definitely towards the right direction. Yet, it is important that equal 
access should be re-established along with the provision of integrated, qualitative 
and undifferentiated care.
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Objectives: Economic evaluation is well regarded by policymakers as a tool 
for healthcare priority setting, but is often not used in practice. We explored the 
perspectives of both users (stakeholders) and producers (health economists) of 
economic evaluations to understand the underutilisation of economic evidence 
in healthcare decision making. MethOds: A mixed methods approach was 
used. Stakeholders (health professionals, healthcare administrators or managers, 
and health researchers) were surveyed regarding to understand the factors that 
determine whether they use evidence from economic evaluations. The relative 
importance of these factors was measured using a discrete choice experiment. 
Perspectives of health economists were gathered through semi-structured inter-
views. Results: The survey was answered by 93 stakeholders. Important factors 
to stakeholders included quality of clinical evidence, quality of economic evidence, 
timeliness, applicability, communication and conflicts of interest. Ten health econo-
mists participated in semi-structured interviews. They discussed methods they 
used to translate their research into healthcare practice. Topics discussed included 
the nature of stakholder engagement and how the production of of economic evi-
dence was tailored to meet specific contextual needs. It was generally considered 
best when stakeholder engagement begins early and is maintained throughout the 
research process. cOnclusiOns: These findings are being used to inform recom-
mendations for translating evidence from economic evaluation into clinical practice. 
Such recommendations need to balance stakeholder needs with the constraints 
that health economists face.
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Objectives: In order to launch a reimbursed drug in France, products with mar-
keting authorization (MA) are firstly assessed by the Transparency Committee (CT, 
Commission de la Transparence) and then undergo pricing negotiations with the 
Pricing Committee (CEPS, Comité Economique des Produits de Santé). This process 
has an impact on time to market launch (ML). The Temporary Authorization for 
Use (ATU) allows early access of drugs to patients before MA and could reduce 
time to ML. Our aim was to compare the time from MA to ML between ATU and 
non-ATU drugs. MethOds: Using the Prismaccess database, research was carried 
out to identify ATU and non-ATU drugs to calculate their time to ML from January 
2013 to June 2015. Mean total time (MA-ML) and mean intermediate times (MA-CT 
opinion and CT opinion-ML) were compared between groups using Mann-Whitney 
test (α = 0.05). Results: French health authorities assessed 7 ATU and 18 non-ATU 
drugs during the reviewed period. The mean total time (MA-ML) was shorter for ATU 
drugs compared to non-ATU drugs (281±58 versus 493±245 days; p= 0.017). Similarly, 
the mean time from MA to CT opinion was shorter for ATU drugs compared to 
non-ATU drugs (141 ± 39 versus 489 ± 727 days; p= 0.004). In contrast, no difference 
was reported in time from CT opinion to ML (143 ± 43 versus 166 ± 101 days; p > 
0.05). cOnclusiOns: Overall, ATU drugs seem to launch faster with respect to the 
total time from MA to ML which is mainly due to the reduced time from MA to CT 
opinion. Indeed, the specific regulatory framework for ATU drugs requires pharma-
ceutical companies to submit a CT dossier within one month of MA. Nevertheless, 
the pricing negotiation process, i.e. time from CT opinion to ML, does not change 
between ATU and non-ATU drugs.
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Objectives: Bosnia and Herzegovina have highly decentralized healthcare system 
which is financed by 12 different health insurance funds (HIF) based on administra-
tive organization of the country. Depending on budget ability different HIFs reim-
